Literature DB >> 33748257

Antibiotic use in children and youths with asthma: a population-based case-control study.

Ivy Fong1, Jingqin Zhu1,2, Yaron Finkelstein1,2,3,4, Teresa To1,2,5.   

Abstract

RATIONALE: Antibiotics are among the most common medications dispensed to children and youths. The objective of this study was to characterise and compare antibiotic use patterns between children and youths with and without asthma.
METHODS: We conducted a population-based nested case-control study using health administrative data from Ontario, Canada, in 2018. All Ontario residents aged 5-24 years with asthma were included as cases. Cases were matched to controls with a 1:1 ratio based on age (within 0.5 year), sex and location of residence. Multivariable conditional logistic regression was used to obtain an odds ratio and 95% confidence interval for having filled at least one antibiotic prescription, adjusted for socioeconomic status, rurality, and presence of common infections, allergic conditions and complex chronic conditions.
RESULTS: The study population included 1 174 424 Ontario children and youths aged 5-24 years. 31% of individuals with asthma and 23% of individuals without asthma filled at least one antibiotic prescription. The odds of having filled at least one antibiotic prescription were 34% higher among individuals with asthma compared to those without asthma (OR 1.34, 95% CI 1.32-1.35). In the stratified analysis, the odds ratios were highest in the youngest group of children studied, aged 5-9 years (OR 1.45, 95% CI 1.41-1.48), and in females (OR 1.36, 95% CI 1.34-1.38).
CONCLUSION: Asthma is significantly associated with increased antibiotic use in children and youths. This association is the strongest in younger children and in females.
Copyright ©The authors 2021.

Entities:  

Year:  2021        PMID: 33748257      PMCID: PMC7957291          DOI: 10.1183/23120541.00944-2020

Source DB:  PubMed          Journal:  ERJ Open Res        ISSN: 2312-0541


Introduction

Antibiotics are among the most common medications dispensed to children and youths [1, 2]. It is estimated that first-line antibiotics contributed to saving ≥17 000 lives in Canada in 2018 [3]. The prevalence of antibiotic prescriptions among children and youths has decreased in recent years [1, 2, 4]. However, there has been increasing concern about unwarranted antibiotic prescribing and increased antibiotic resistance, and subsequent calls by authorities for more research and investment in resources to reverse these trends [3, 5]. This study aimed to address this need by characterising antibiotic use patterns among children and youths with asthma. Asthma affects ∼339 million individuals worldwide [6]. It is the most common chronic condition in childhood [6], affecting one in eight children [7]. Examining antibiotic use among children and youths with asthma is important due to the high prevalence of asthma, and because antibiotic use may lead to increased healthcare costs and adverse drug events such as allergic reactions, neurotoxic effects and infection with antibiotic-resistant organisms [8, 9]. The use of multiple drugs (i.e. polypharmacy) has been identified as an important predictor of adverse drug events in children [10]. Children with asthma could potentially be at greater risk of experiencing adverse drug events because they may use multiple drugs, including inhaled corticosteroids and antibiotics [11]. A recent retrospective cohort study using a discordant twin design reported that children exposed to antibiotic use in early life may be at increased risk of developing asthma [12]. Previous studies on early-life antibiotic exposure and later asthma development have been criticised for study limitations such as poor data collection methods and small sample size, and researchers have suggested that future studies should examine the number of antibiotics used in early life [12, 13]. In the existing literature on antibiotic use among children and youths with asthma, few studies have used comprehensive population-based data. Previous studies that included only individuals enrolled in participating primary care practices [14] or health plans [15] may be subject to selection bias and their results may not be representative of the general population of children and youths. Thus, the objective of this study was to use population-based data to characterise and compare antibiotic use patterns between children and youths with and without asthma. This was examined in a population of 1 174 424 individuals aged 5–24 years from Ontario, Canada.

Methods

Study design

To characterise and compare antibiotic use patterns between children and youths with and without asthma, we conducted a population-based nested case–control study from 1 January 2018 to 31 December 2018 using health administrative data from Ontario, Canada. The study population included Ontario children and youths aged 5–24 years.

Study population

Individuals with a physician diagnosis of asthma were identified using a validated health administrative definition of at least one hospitalisation for asthma or at least two outpatient visits for asthma in two consecutive years. This case definition has been validated [16] and used in previous studies [17-19]. All Ontario residents aged 5–24 years with asthma were included as cases in this study. Asthma cases were matched to nonasthma controls with a 1:1 ratio based on age (within 0.5 year), sex and location of residence as defined by local health integration networks (LHINs). LHINs are geographical regions established across Ontario to plan, fund and coordinate local community-based health services [20]. Individuals were excluded from the study if they were ever diagnosed with diabetes, cancer or COPD, or if they ever had an organ transplant. Individuals were also excluded if they did not have a valid Ontario health card number or Ontario residence code, or if they had missing data on covariates.

Data sources

This population-based study used Ontario health administrative data linked using unique coded identifiers at ICES (formerly the Institute for Clinical Evaluative Sciences) in Toronto, Ontario. Health administrative data are routinely collected through Ontario's publicly funded healthcare system. During the 2018 study period, free public prescription drug coverage was available to all Ontario residents aged 0–24 years through the Ontario Health Insurance Plan Plus (OHIP+) programme [21]. The OHIP+ programme covered the full cost of >4400 drugs, including almost all oral antibiotics [21]. With the OHIP+ programme, the prescription drug claims of the study population during the study period were captured in provincial health administrative data. Health administrative databases used in this study included the Registered Persons Database (sociodemographic information), Discharge Abstract Database (hospital admissions), National Ambulatory Care Reporting System (emergency department visits), Ontario Health Insurance Plan Claims Database (outpatient physician visit claims), Ontario Drug Benefit Claims Database (prescriptions filled), Ontario Asthma Surveillance Information System (asthma), Ontario Diabetes Database (diabetes), Ontario Cancer Registry (cancer) and Chronic Obstructive Pulmonary Disease Database (COPD).

Outcome definition

The primary outcome of antibiotic use was defined as a binary variable by whether an individual filled at least one antibiotic prescription. All antibiotics eligible for coverage through the OHIP+ programme were included. Additionally, the use of antibiotic classes commonly prescribed for bacterial respiratory infections, i.e. cephalosporins, macrolides and penicillins, were examined combined as one secondary outcome and separately by class.

Covariates

Socioeconomic status was measured using the Ontario Marginalization Index. The Ontario Marginalization Index uses census data to measure four dimensions of marginalisation (material deprivation, dependency, ethnic concentration and residential instability) at the neighbourhood level [22]. Individuals are assigned a value from 1 (least marginalised) to 5 (most marginalised) for each dimension based on their residence neighbourhood [22]. Residence was defined as rural if an individual resided in a community of ≤10 000 people [20]. Otherwise, residence was defined as urban [20]. The presence of common infections and allergic conditions, including bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection and appendicitis [23-25], was defined as any health service claim for these conditions identified using International Classification of Diseases, 10th Revision (ICD-10), Ontario Health Insurance Plan and Canadian Classification of Health Interventions codes (table S1). The presence of complex chronic conditions, as described previously [26], was defined as any hospitalisation for these conditions identified using ICD-10 codes (table S2).

Statistical analysis

Baseline characteristics of the study population were described with the frequency and proportion of categorical variables, and the mean and standard deviation of continuous variables. Antibiotic use was described with the frequency and proportion of individuals who filled at least one prescription for each antibiotic category, and stratified by age and sex subgroups. Differences in baseline characteristics and antibiotic use between asthma cases and nonasthma controls were compared using standardised difference scores to provide a statistical measure of differences between groups that is not influenced by the large sample size [27, 28]. Multivariable conditional logistic regression was used to obtain an adjusted odds ratio and 95% confidence interval for having filled at least one antibiotic prescription, comparing asthma cases and nonasthma controls. Cases were matched to controls on age (within 0.5 year), sex and location of residence, and the remaining unmatched variables of socioeconomic status, rurality, and presence of common infections, allergic conditions and complex chronic conditions were included in the model. The definitions of these variables are outlined in the Covariates section. The model was repeated for each antibiotic category, and stratified by age and sex subgroups. A p-value of <0.05 was used to determine statistical significance. All analyses were carried out using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Research ethics

Ethics approval was obtained from the Hospital for Sick Children Research Ethics Board in Toronto, Ontario. Individual consent was not required as only deidentified provincial health administrative data were used in this study.

Results

Characteristics of the study population

The study population included 1 174 424 Ontario children and youths aged 5–24 years. Most were male (58.5%) and the largest age group was adolescents aged 15–19 years (29.2%) (table 1). Among individuals with asthma, the mean±sd asthma duration was 11.6±6.0 years. Asthma cases and nonasthma controls were distributed equally across the Ontario Marginalization Index dimensions. Most asthma cases (92.9%) and nonasthma controls (91.8%) lived in urban areas. A higher proportion of individuals with asthma had bronchitis (5.2%) and allergic rhinitis (5.2%) compared to individuals without asthma (3.0% and 3.0%, respectively). The characteristics of the study population by type of antibiotic received are presented in the supplementary material (table S3).
TABLE 1

Characteristics of the study population by asthma diagnosis (N=1 174 424)

CharacteristicAsthma cases#Nonasthma controls#Standardised difference
Age group at baseline years
 5–9115 189 (19.6%)115 189 (19.6%)0.000
 10–14147 737 (25.2%)147 737 (25.2%)0.000
 15–19171 356 (29.2%)171 356 (29.2%)0.000
 20–24152 930 (26.0%)152 930 (26.0%)0.000
Sex
 Female243 969 (41.5%)243 969 (41.5%)0.000
 Male343 243 (58.5%)343 243 (58.5%)0.000
Asthma duration years mean±sd11.6±6.0
Ontario Marginalization Index
 Deprivation quintile
  1, lowest133 636 (22.8%)131 345 (22.4%)0.009
  2128 432 (21.9%)126 630 (21.6%)0.007
  3111 763 (19.0%)111 344 (19.0%)0.002
  4101 696 (17.3%)103 949 (17.7%)0.010
  5, highest111 685 (19.0%)113 944 (19.4%)0.010
 Dependency quintile
  1, lowest194 920 (33.2%)192 883 (32.8%)0.007
  2129 077 (22.0%)128 180 (21.8%)0.004
  3100 243 (17.1%)100 692 (17.1%)0.002
  488 636 (15.1%)89 773 (15.3%)0.005
  5, highest74 336 (12.7%)75 684 (12.9%)0.007
 Ethnic Concentration Quintile
  1, lowest66 831 (11.4%)68 204 (11.6%)0.007
  283 814 (14.3%)81 572 (13.9%)0.011
  3101 785 (17.3%)97 088 (16.5%)0.021
  4132 846 (22.6%)127 439 (21.7%)0.022
  5, highest201 936 (34.4%)212 909 (36.3%)0.039
 Residential Instability Quintile
  1, lowest172 074 (29.3%)162 727 (27.7%)0.035
  2117 815 (20.1%)115 345 (19.6%)0.011
  3101 220 (17.2%)101 141 (17.2%)0.000
  498 530 (16.8%)97 822 (16.7%)0.003
  5, highest97 573 (16.6%)110 177 (18.8%)0.056
Rurality
 Urban545 302 (92.9%)539 000 (91.8%)0.040
 Rural41 910 (7.1%)48 212 (8.2%)0.040
Presence of common infections and allergic conditions
 Bronchitis30 447 (5.2%)17 859 (3.0%)0.108
 Influenza8217 (1.4%)5835 (1.0%)0.037
 Pneumonia8564 (1.5%)4542 (0.8%)0.065
 Allergic rhinitis30 684 (5.2%)17 525 (3.0%)0.113
 Eczema41 825 (7.1%)30 477 (5.2%)0.080
 Tonsillitis and adenoiditis21 561 (3.7%)15 831 (2.7%)0.056
 Ear infection39 570 (6.7%)28 824 (4.9%)0.078
 Appendicitis1837 (0.3%)1482 (0.3%)0.011
Presence of any complex chronic condition
 Yes1465 (0.2%)924 (0.2%)0.020
 No585 747 (99.8%)586 288 (99.8%)0.020

#: n=587 212; ¶: standardised difference >0.1 generally considered different (shown in bold).

Characteristics of the study population by asthma diagnosis (N=1 174 424) #: n=587 212; ¶: standardised difference >0.1 generally considered different (shown in bold).

Antibiotic use

A larger proportion of individuals with asthma filled at least one antibiotic prescription; 30.6% of asthma cases compared to 23.1% of nonasthma controls (table 2). Similarly, 26.4% of asthma cases and 19.5% of nonasthma controls filled at least one antibiotic prescription commonly prescribed for respiratory infections. The same pattern was observed across all age and sex subgroups for each antibiotic category.
TABLE 2

Number of individuals who filled at least one antibiotic prescription by asthma diagnosis, age group and sex (N=1 174 424)

Antibiotic prescriptions by age group and sexIndividuals that filled ≥1 antibiotic prescriptionStandardised difference
Asthma cases#Nonasthma controls#
All antibiotics
 All179 937 (30.6%)135 697 (23.1%)0.171
 5–9 years old43 675 (37.9%)31 216 (27.1%)0.232
 10–14 years old39 210 (26.5%)27 949 (18.9%)0.183
 15–19 years old53 901 (31.5%)41 876 (24.4%)0.157
 20–24 years old43 151 (28.2%)34 656 (22.7%)0.128
 Female84 318 (34.6%)63 526 (26.0%)0.186
 Male95 619 (27.9%)72 171 (21.0%)0.159
Antibiotics commonly prescribed for respiratory infections
 All155 210 (26.4%)114 540 (19.5%)0.165
 5–9 years old40 947 (35.5%)28 939 (25.1%)0.228
 10–14 years old34 492 (23.3%)23 967 (16.2%)0.180
 15–19 years old44 706 (26.1%)33 841 (19.7%)0.151
 20–24 years old35 065 (22.9%)27 793 (18.2%)0.118
 Female72 982 (29.9%)53 868 (22.1%)0.179
 Male82 228 (24.0%)60 672 (17.7%)0.155
Cephalosporins
 All14 234 (2.4%)9147 (1.6%)0.062
 5–9 years old4856 (4.2%)2992 (2.6%)0.089
 10–14 years old3339 (2.3%)2010 (1.4%)0.068
 15–19 years old3388 (2.0%)2276 (1.3%)0.051
 20–24 years old2651 (1.7%)1869 (1.2%)0.042
 Female6759 (2.8%)4420 (1.8%)0.064
 Male7475 (2.2%)4727 (1.4%)0.061
Macrolides
 All54 382 (9.3%)34 654 (5.9%)0.127
 5–9 years old11 665 (10.1%)6820 (5.9%)0.155
 10–14 years old12 243 (8.3%)7207 (4.9%)0.138
 15–19 years old16 390 (9.6%)10 687 (6.2%)0.124
 20–24 years old14 084 (9.2%)9940 (6.5%)0.101
 Female25 753 (10.6%)16 372 (6.7%)0.137
 Male28 629 (8.3%)18 282 (5.3%)0.120
Penicillins
 All109 922 (18.7%)84 606 (14.4%)0.116
 5–9 years old31 817 (27.6%)23 133 (20.1%)0.178
 10–14 years old23 673 (16.0%)17 297 (11.7%)0.125
 15–19 years old31 258 (18.2%)24 853 (14.5%)0.101
 20–24 years old23 174 (15.2%)19 323 (12.6%)0.073
 Female52 033 (21.3%)40 063 (16.4%)0.126
 Male57 889 (16.9%)44 645 (13.0%)0.109

#: n=587 212; ¶: standardised difference >0.1 generally considered different (shown in bold).

Number of individuals who filled at least one antibiotic prescription by asthma diagnosis, age group and sex (N=1 174 424) #: n=587 212; ¶: standardised difference >0.1 generally considered different (shown in bold). Among individuals with asthma, antibiotic use did not differ by asthma duration but was higher among those with more recently diagnosed asthma (table S4). A similar pattern was observed for antibiotics commonly prescribed for respiratory infections and penicillins. There was no statistical difference in cephalosporin and macrolide use by asthma duration.

Adjusted odds of having filled at least one antibiotic prescription

In the multivariable conditional logistic regression analysis, the adjusted odds of having filled at least one antibiotic prescription were 34% higher among children and youths with asthma compared to individuals without asthma (OR 1.34, 95% CI 1.32–1.35) (table 3). Similarly, the odds of having filled at least one antibiotic prescription commonly prescribed for respiratory infections were 35% higher among children and youth with asthma compared to individuals without asthma (OR 1.35, 95% CI 1.33–1.36). The odds were also higher among individuals with asthma across all age and sex subgroups for each antibiotic category (figures 1 and 2). The unadjusted and adjusted odds ratios for the age and sex subgroups are presented in the supplementary material (table S5).
TABLE 3

Unadjusted and adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression (N=1 174 424)

Antibiotic prescriptionsUnadjustedAdjusted
OR (95% CI)p-value#OR (95% CI)p-value#
All antibiotics1.48 (1.47–1.49)<0.00011.34 (1.32–1.35)<0.0001
Antibiotics commonly prescribed for respiratory infections1.50 (1.48–1.51)<0.00011.35 (1.33–1.36)<0.0001
Cephalosporins1.57 (1.53–1.62)<0.00011.37 (1.33–1.41)<0.0001
Macrolides1.63 (1.61–1.65)<0.00011.46 (1.43–1.48)<0.0001
Penicillins1.38 (1.36–1.39)<0.00011.25 (1.24–1.27)<0.0001

The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions. #: p <0.05 was used to determine statistical significance.

FIGURE 1

Adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression by age group (N=1 174 424). The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions.

FIGURE 2

Adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression by sex (N=1 174 424). The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions.

Unadjusted and adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression (N=1 174 424) The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions. #: p <0.05 was used to determine statistical significance. Adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression by age group (N=1 174 424). The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions. Adjusted odds of having filled at least one antibiotic prescription for children and youths with asthma versus without asthma from conditional logistic regression by sex (N=1 174 424). The conditional logistic regression models were adjusted for Ontario Marginalization Index, rurality, bronchitis, influenza, pneumonia, allergic rhinitis, eczema, tonsillitis, adenoiditis, ear infection, appendicitis and complex chronic conditions. In the age-stratified analysis, the odds of having filled at least one antibiotic prescription were highest in the youngest group of children studied, aged 5–9 years (OR 1.45, 95% CI 1.41–1.48) (figure 1). The odds ratios decreased in a stepwise fashion with increasing age. Similarly, the odds of having filled at least one antibiotic prescription commonly prescribed for respiratory infections were also highest in children aged 5–9 years (OR 1.45, 95% CI 1.42–1.49). The odds ratios for antibiotic prescriptions commonly prescribed for respiratory infections also decreased in a stepwise fashion with increasing age. The same pattern was observed for penicillins. A similar pattern was observed for cephalosporins and macrolides but for these antibiotic classes, the odds were highest in children aged 10–14 years. In the sex-stratified analysis, the odds of having filled at least one antibiotic prescription were higher in females (OR 1.36, 95% CI 1.34–1.38) (figure 2) than males. The odds of having filled at least one antibiotic prescription commonly prescribed for respiratory infections were also higher in females (OR 1.36, 95% CI 1.34–1.38). The same pattern was observed for penicillins but not for cephalosporins or macrolides.

Discussion

To our knowledge, this is the largest population-based study to date on antibiotic use in children and youths with and without asthma. We found that 30.6% of individuals with asthma and 23.1% of individuals without asthma filled at least one antibiotic prescription. The odds of having filled at least one antibiotic prescription were significantly higher among children and youths with asthma compared to individuals without asthma. In the stratified analysis, we found that the odds were highest in the youngest group of children studied, aged 5–9 years, and in females. A similar pattern was observed for antibiotics commonly prescribed for respiratory infections, including cephalosporins, macrolides and penicillins. Stallworth et al. [15] found that antibiotic use was significantly increased in US children aged 5–18 years with asthma for respiratory, nonrespiratory, bacterial and viral conditions. Similarly, Baan et al. [29] found that antibiotic use was significantly higher in UK and Dutch children aged 5–18 years with asthma. The authors also found that one in seven children with asthma received antibiotics during asthma exacerbation. Healthcare providers may prescribe antibiotics during asthma exacerbation to treat or prevent potential secondary respiratory infections and because the anti-inflammatory effects of antibiotics, particularly macrolides, may be useful for controlling inflammation in individuals with asthma [30, 31]. However, antibiotic use is associated with increased risk of dysbiosis in the airway, which may lead to increased inflammation [32]. We found that asthma was significantly associated with increased odds of use of antibiotics commonly prescribed for respiratory infections in children and youths. Hak et al. [14] found that antibiotic prescriptions were higher in children with asthma aged 2–12 years because upper respiratory tract infections such as rhinitis, sinusitis and laryngitis were more common in these children. Similarly, Baan et al. [29] found that antibiotics were prescribed more often to children with asthma for lower respiratory tract infections, such as pneumonia. The authors suggested that children with asthma may receive more antibiotic prescriptions because it may be particularly challenging to distinguish between bacterial and viral lower respiratory tract infections in children with asthma [29]. In the age-stratified analysis, we found that the association between asthma and antibiotic use was the strongest in the youngest group of children studied, aged 5–9 years. Among Belgian children aged 0–18 years, De Boeck et al. [33] found that antibiotic prescriptions decreased with age. In a study of antibiotic use in Northern Italy, Franchi et al. [34] also found that antibiotics prescribed to children decreased with age toward adolescence. Higher antibiotic use may be attributable to the increased frequency of infections among younger children [35]. In the sex-stratified analysis, we found that the association between asthma and antibiotic use was stronger in females than males. Similarly, Stallworth et al. [15] found that antibiotic use was higher among females with asthma. Previous research has demonstrated that young girls with asthma may experience less asthma symptoms, such as wheezing, compared to boys [15, 36]. This may lead to less aggressive treatment of asthma with inhaled corticosteroids, which could lead to a greater risk of secondary infections requiring antibiotic therapy in young girls [15]. Additionally, because of their anatomy, females are more susceptible to infections such as urinary tract infections and pelvic inflammatory disease, which may lead to increased antibiotic use compared to males [37, 38]. Antibiotic use was observed in nearly one in three individuals with asthma and one in four individuals without asthma. Exposure to antibiotic use in early life, especially antibiotics prescribed for respiratory infections, may lead to increased risk of asthma [12]. As such, physicians should consider the potential risks and benefits of antibiotics prescriptions for young children [12]. The higher odds of antibiotic use observed in children and youths with asthma may be a result of antibiotic prescriptions for asthma exacerbation [29], and the higher risk of infections among individuals with asthma [14, 29, 39], younger children [35] and females [15]. Researchers, physicians and policy-makers should identify and implement novel strategies, and strengthen existing strategies to prevent asthma exacerbations and minimise infections that lead to antibiotic use in children and youths with asthma (e.g. strengthen existing strategies to limit exposure to asthma triggers such as tobacco smoke through legislation, promote influenza vaccination, provide education on preventing common infections such as urinary tract infections, and increase adherence to inhaled corticosteroid maintenance treatment in children with asthma). In this study, health administrative data was used to collect information about antibiotic prescriptions filled by children and youths in Ontario. The use of health administrative data limited our ability to examine potentially relevant variables such as ethnicity, asthma severity and parental allergy. Our ability to examine the indications for which antibiotics were prescribed was also limited. Some children may have been prescribed antibiotics for respiratory viral conditions, which do not require antibiotics. This data source allowed us to study medication use without selection or response bias in a large population, which may allow us to generalise our results to populations in other jurisdictions. Notably, since public drug coverage was available to all Ontario residents aged 0–24 years during the study period, a strength of this study is that antibiotic use was not affected by socioeconomic status, the ability to pay for prescriptions or health insurance coverage. Future research should examine the relationship between asthma severity and antibiotic use, as well as the dose–response relationship between asthma and antibiotic use. Future research should also examine the association between use of inhaled corticosteroids, β2-agonists and antibiotics among individuals with asthma.

Conclusion

In this population-based study, the largest on this topic to date, we found that asthma is significantly associated with increased odds of antibiotic use in children and youths. This association is strongest in younger children and in females. Researchers, physicians and policy-makers should identify and implement novel strategies, and strengthen existing strategies to prevent asthma exacerbations and minimise infections that lead to antibiotic use in children and youths with asthma. Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author. Supplementary material 00944-2020.SUPPLEMENT
  30 in total

1.  Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.

Authors:  M Diane Lougheed; Catherine Lemiere; Francine M Ducharme; Chris Licskai; Sharon D Dell; Brian H Rowe; Mark Fitzgerald; Richard Leigh; Wade Watson; Louis-Philippe Boulet
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

2.  Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma.

Authors:  Natasha Gray; Andrew Howard; Jingqin Zhu; Laura Y Feldman; Teresa To
Journal:  JAMA Pediatr       Date:  2018-01-01       Impact factor: 16.193

3.  Trends in common surgical procedures at children's and nonchildren's hospitals between 2000 and 2009.

Authors:  Heather L Short; Samir Sarda; Curtis Travers; Jason M Hockenberry; Ian McCarthy; Mehul V Raval
Journal:  J Pediatr Surg       Date:  2017-11-23       Impact factor: 2.545

Review 4.  Macrolides for chronic asthma.

Authors:  Kayleigh M Kew; Krishna Undela; Ioanna Kotortsi; Giovanni Ferrara
Journal:  Cochrane Database Syst Rev       Date:  2015-09-15

5.  Trends of outpatient prescription drug utilization in US children, 2002-2010.

Authors:  Grace Chai; Laura Governale; Ann W McMahon; James Phillip Trinidad; Judy Staffa; Dianne Murphy
Journal:  Pediatrics       Date:  2012-06-18       Impact factor: 7.124

6.  Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980-1997.

Authors:  C Feudtner; D A Christakis; F A Connell
Journal:  Pediatrics       Date:  2000-07       Impact factor: 7.124

7.  Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study.

Authors:  S Dresden Glockler-Lauf; Yaron Finkelstein; Jingqin Zhu; Laura Y Feldman; Teresa To
Journal:  J Pediatr       Date:  2019-03-21       Impact factor: 4.406

8.  Identifying patients with physician-diagnosed asthma in health administrative databases.

Authors:  Andrea S Gershon; Chengning Wang; Jun Guan; Jovonka Vasilevska-Ristovska; Lisa Cicutto; Teresa To
Journal:  Can Respir J       Date:  2009 Nov-Dec       Impact factor: 2.409

Review 9.  Impact of gender on asthma in childhood and adolescence: a GA2LEN review.

Authors:  C Almqvist; M Worm; B Leynaert
Journal:  Allergy       Date:  2007-09-05       Impact factor: 13.146

10.  Consumption of antibiotics by children in Greece: a cross-sectional study.

Authors:  Helena C Maltezou; Xanthi Dedoukou; Hara Asimaki; Ioanna Kontou; Loukia Ioannidou; Konstantina Mitromara; Kalliopi Theodoridou; Panos Katerelos; Maria Theodoridou
Journal:  Int J Pediatr Adolesc Med       Date:  2017-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.